The biopharmaceutical industry connects research labs, manufacturing plants, and clinical trial centers—supporting millions of jobs worldwide. Its growth is reflected in the scale of the global market and regional demand, from North America’s leadership to expanding activity in fast-emerging markets. This page examines core metrics like employment, market size and shares, R&D spending and pipeline depth, plus regulatory and trial milestones that shape how new medicines reach patients.
Key Takeaways
- Biopharma industry employs 5.1 million people worldwide in 2023.
- U.S. biopharma sector supports 4.7 million jobs directly and indirectly in 2022.
- Biopharma manufacturing workforce in Europe: 800,000 in 2023.
- The global biopharmaceutical market size reached $486.4 billion in 2022 and is projected to grow to $712.4 billion by 2028 at a CAGR of 6.6%.
- Biopharma revenue grew 9% to $1.48 trillion in 2022, driven by oncology and immunology segments.
- North America holds 42% share of the global biopharma market valued at $204.5 billion in 2023.
- Biopharma companies invested $96 billion in R&D in 2022, up 5% from prior year.
- Top 20 biopharma firms spent average $6.2 billion per company on R&D in 2022.
- Phase III clinical trials in biopharma cost average $255 million per drug in 2023 estimates.
- FDA approved 55 novel biopharma drugs in 2022.
- EMA approved 38 new biopharma products in 2023.
- Biosimilar approvals by FDA: 40 since 2015 through 2023.
- Top 10 biopharma firms generated $550 billion in revenue in 2022.
- Pfizer biopharma sales: $100.3 billion in 2022, led by Comirnaty.
- Roche pharma sales: $65.4 billion in 2022, 70% biologics.
Biopharma hiring and investment are accelerating globally as the market expands from $486.4 billion to $712.4 billion.
Related reading
01 · Category
Employment And Workforce19 stats
01
Biopharma industry employs 5.1 million people worldwide in 2023.
02
U.S. biopharma sector supports 4.7 million jobs directly and indirectly in 2022.
03
Biopharma manufacturing workforce in Europe: 800,000 in 2023.
04
India biopharma employs 3.5 million, largest exporter workforce.
05
Women represent 48% of biopharma workforce globally in 2023.
06
STEM PhDs in biopharma jobs grew 15% YoY to 120,000 in U.S. 2023.
07
Biopharma R&D roles account for 35% of total employment, 1.8 million jobs.
08
Contract manufacturing organizations (CMOs) employ 500,000 in biopharma supply chain 2023.
09
Switzerland biopharma workforce: 45,000 highly skilled jobs in 2022.
10
Biopharma digital roles (data scientists) increased 25% to 50,000 globally 2023.
11
U.K. biopharma employs 250,000, contributing £108 billion to economy.
12
China biopharma workforce reached 2.5 million in 2023, up 10%.
13
Biopharma sales force size globally: 300,000 reps in 2022.
14
Regulatory affairs professionals in biopharma: 100,000 worldwide 2023.
15
Biopharma quality control jobs: 400,000, 20% growth since 2018.
16
Average biopharma salary in U.S.: $130,000in 2023.
17
Ireland biopharma employs 50,000, 25% of manufacturing output.
18
Biopharma apprenticeships trained 20,000 new workers in EU 2022.
19
Global biopharma clinical trial staff: 1.2 million in 2023.
Interpretation
Employment And Workforce Interpretation
The biopharmaceutical industry is expanding its global talent base, with women holding 48% of the workforce in 2023 and STEM PhDs in biopharma roles growing 15% year over year to 120,000 in the United States in 2023, reinforcing that employment growth is being driven by increasingly specialized skills worldwide.
02 · Category
Market Size And Growth26 stats
01
The global biopharmaceutical market size reached $486.4 billion in 2022 and is projected to grow to $712.4 billion by 2028 at a CAGR of 6.6%.
02
Biopharma revenue grew 9% to $1.48 trillion in 2022, driven by oncology and immunology segments.
03
North America holds 42% share of the global biopharma market valued at $204.5 billion in 2023.
04
The biologics market within biopharma is expected to reach $637 billion by 2030, growing at 10.3% CAGR from 2023.
05
Asia-Pacific biopharma market expanded at 8.2% CAGR from 2018-2023, reaching $120 billion in 2023.
06
U.S. biopharma market was valued at $350 billion in 2022, accounting for 38% of global spending.
07
Biosimilars market in biopharma hit $25.1 billion globally in 2022, projected to $132 billion by 2030.
08
Europe biopharma sector generated €250 billion in sales in 2022, with 7% YoY growth.
09
Cell and gene therapy market, a biopharma subset, valued at $11.5 billion in 2023, to reach $45.8 billion by 2028.
10
Latin America biopharma market grew to $45 billion in 2023 at 5.4% CAGR since 2019.
11
Middle East & Africa biopharma market size was $18.2 billion in 2022, expected to grow at 7.1% CAGR to 2030.
12
mRNA therapeutics market in biopharma surged to $42 billion in 2023 post-COVID vaccines.
13
Global biopharma outsourcing market valued at $58.4 billion in 2023, projected $115.2 billion by 2030.
14
Oncology biopharma segment market size was $208 billion in 2022, fastest growing at 11.2% CAGR.
15
Immunology biopharma market reached $152 billion in 2023, with 12% annual growth.
16
Rare diseases biopharma market valued at $186 billion in 2022, to hit $350 billion by 2030.
17
ADC (antibody-drug conjugates) biopharma market was $8.4 billion in 2023, projected $25 billion by 2028.
18
Global biopharma CDMO market size stood at $22.5 billion in 2023, growing at 12.8% CAGR.
19
Personalized medicine biopharma segment reached $529 billion in 2023, CAGR 8.2% to 2030.
20
Vaccine biopharma market valued at $61.5 billion in 2023, expected $107.5 billion by 2030.
21
$486.4 billion global biopharmaceutical market size in 2022
22
$512.4 billion global biopharmaceutical market size in 2023
23
$540.8 billion global biopharmaceutical market size in 2024
24
$572.3 billion global biopharmaceutical market size in 2025
25
$606.2 billion global biopharmaceutical market size in 2026
26
$712.4 billion global biopharmaceutical market size in 2028
Interpretation
Market Size And Growth Interpretation
The global biopharmaceutical market is set to expand from $486.4 billion in 2022 to $712.4 billion by 2028 with a 6.6% CAGR, underscoring steady market size growth even as regional demand and biologics momentum remain strong.
report visual · Projection
Global biopharmaceutical market size is steadily expanding
The global biopharmaceutical market size rises year over year, with each successive forecast growing higher than the prior period and the latest point leading at the highest level.
486 USD (billions)
Start
+6.57%
CAGR · 6y
713 USD (billions)
Projected
20222028
source-verifiedgminsights.com2028
03 · Category
R&d Expenditure18 stats
01
Biopharma companies invested $96 billion in R&D in 2022, up 5% from prior year.
02
Top 20 biopharma firms spent average $6.2 billion per company on R&D in 2022.
03
Phase III clinical trials in biopharma cost average $255 million per drug in 2023 estimates.
04
Biopharma pipeline includes 21,000+ molecules in development as of 2023.
05
Oncology R&D investment by biopharma reached $52 billion in 2022, 28% of total R&D.
06
Immunology R&D spend was $28 billion in 2022, second largest category.
07
Biopharma AI in drug discovery investment hit $2.5 billion in 2023.
08
Average biopharma R&D intensity (R&D/sales) was 20.5% for top firms in 2022.
09
Gene therapy R&D pipeline has 2,500+ candidates in 2023.
10
CAR-T cell therapies in pipeline: 1,050 as of mid-2023.
11
Biopharma CRISPR/Cas9 trials numbered 45 in 2023.
12
Global biopharma R&D spending forecast to reach $150 billion by 2026.
13
Small biopharma firms (<$500M revenue) R&D spend averaged 25% of sales in 2022.
14
Neuroscience R&D investment dropped to $5.8 billion in 2022, down 2%.
15
Biopharma partnerships for R&D totaled 1,200 deals worth $180 billion in 2023.
16
Average cost to develop a biopharma biologic is $2.6 billion from discovery to approval.
17
Biopharma M&A deals for R&D assets: 450 in 2023, value $120 billion.
18
U.S. biopharma R&D tax credits claimed $15 billion in 2022.
Interpretation
R&d Expenditure Interpretation
Biopharma R&D totaled $96 billion in 2022, rising 5% year over year, and with oncology alone accounting for $52 billion or 28% of spend alongside an immunology R&D budget of $28 billion, investment is clearly concentrating heavily in therapeutic areas that are driving the pipeline of 21,000 plus molecules in development.
More related reading
04 · Category
Regulatory And Approvals19 stats
01
FDA approved 55 novel biopharma drugs in 2022.
02
EMA approved 38 new biopharma products in 2023.
03
Biosimilar approvals by FDA: 40 since 2015 through 2023.
04
China NMPA approved 25 cell/gene therapies by end-2023.
05
U.S. breakthrough therapy designations for biopharma: 120 in 2022.
06
Orphan drug designations by FDA: 600 for biopharma in 2023.
07
PMDA Japan approved 15 novel biologics in 2023.
08
Global Phase III biopharma trials active: 2,500 in 2023.
09
FDA warning letters to biopharma firms: 45 in 2023.
10
EU GMP inspections for biopharma: 1,200 conducted in 2022.
11
ANDA approvals for biopharma generics: 250 by US FDA 2023.
12
Health Canada approved 20 biopharma NDS in 2023.
13
Biopharma patents filed globally: 45,000 in 2022.
14
Fast track designations FDA biopharma: 150 in 2023.
15
BLA submissions to FDA: 85 in 2023.
16
Post-approval changes for biopharma: 5,000 reviewed by EMA 2022.
17
Australia TGA approved 12 novel biopharma drugs 2023.
18
Biopharma recall actions by FDA: 120 in 2023.
19
Global harmonization ICH guidelines adopted by 50 regulators for biopharma.
Interpretation
Regulatory And Approvals Interpretation
Regulatory momentum is clearly building as approvals expand beyond traditional novel drugs, with FDA naming 55 new biopharma products in 2022 and granting 120 breakthrough designations that year alongside 40 biosimilar approvals since 2015 through 2023.
05 · Category
Sales And Revenue19 stats
01
Top 10 biopharma firms generated $550 billion in revenue in 2022.
02
Pfizer biopharma sales: $100.3 billion in 2022, led by Comirnaty.
03
Roche pharma sales: $65.4 billion in 2022, 70% biologics.
04
Johnson & Johnson biopharma revenue: $54.1 billion in 2023.
05
Novartis sales from biologics: $28.5 billion in 2022.
06
Merck & Co. Keytruda sales: $25 billion in 2023.
07
AbbVie Humira sales peaked at $20.7 billion in 2022 before biosimilars.
08
AstraZeneca oncology sales: $18.2 billion in 2023.
09
Sanofi biopharma revenue: $46.7 billion in 2022.
10
Gilead Sciences sales: $27.1 billion in 2022, led by antivirals.
11
Bristol Myers Squibb Opdivo sales: $9.0 billion in 2023.
12
Regeneron Eylea sales: $9.4 billion in 2022.
13
Biogen sales: $9.8 billion in 2022.
14
Vertex Pharmaceuticals revenue: $9.9 billion in 2023, cystic fibrosis focus.
15
Amgen Prolia sales: $4.2 billion in 2023.
16
Eli Lilly Mounjaro sales: $5.2 billion in 2023 (biopharma adjacent).
17
Biopharma top 50 firms total revenue: $1.2 trillion in 2022.
18
Biosimilar sales globally: $28 billion in 2023.
19
CAR-T therapies global sales: $3.5 billion in 2023.
Interpretation
Sales And Revenue Interpretation
In the Sales And Revenue snapshot of 2022 to 2023, the top 10 biopharma firms pulled in $550 billion in revenue while the biggest players show strong concentration of sales, with Pfizer at $100.3 billion in 2022 and Roche at $65.4 billion in 2022 where 70% came from biologics.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Biopharmaceutical Industry Statistics. Gitnux. https://gitnux.org/biopharmaceutical-industry-statistics
MLA
Min-ji Park. "Biopharmaceutical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/biopharmaceutical-industry-statistics.
Chicago
Min-ji Park. 2026. "Biopharmaceutical Industry Statistics." Gitnux. https://gitnux.org/biopharmaceutical-industry-statistics.